Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK

12 Jul 2023

Abstract excerpt

Gemcitabine is a nucleoside analog that has been successfully used in the treatment of multiple cancers. However, intrinsic or acquired resistance reduces the chemotherapeutic potential of gemcitabine. Here, we revealed a previously unappreciated mechanism by which phosphatase and tensin homolog (PTEN), one of the most frequently mutated genes in human cancers, dominates the decision-making process that is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Pancreatic and Hepatic Oncology Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37437018
DOI: 10.1126/scitranslmed.add7464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCKPMID 37437018Read ↗

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read ↗

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read ↗

Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cellsSemantic proximity Read ↗

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell LinesSemantic proximity Read ↗

PI(3)king apart PTEN's role in cancer.Semantic proximity Read ↗

Therapeutic targeting of cancers with loss of PTEN function.Semantic proximity Read ↗

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancerSemantic proximity Read ↗

Targeting mTOR dependency in pancreatic cancer.Semantic proximity Read ↗

A Novel PI3K-driven Mouse Model of Intrahepatic Cholangiocarcinoma and Synergistic Antitumor Effects of Combined PI3K and WEE1 InhibitionSemantic proximity Read ↗

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 LevelsSemantic proximity Read ↗

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.Semantic proximity Read ↗

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.